Literature DB >> 21677110

Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration.

Camila Mathias-Santos1, Juliana F Rodrigues, Maria Elisabete Sbrogio-Almeida, Terry D Connell, Luís C S Ferreira.   

Abstract

The type I and type II heat-labile enterotoxins (LT-I and LT-II) are strong mucosal adjuvants when they are coadministered with soluble antigens. Nonetheless, data on the parenteral adjuvant activities of LT-II are still limited. Particularly, no previous study has evaluated the adjuvant effects and induced inflammatory reactions of LT-II holotoxins or their B pentameric subunits after delivery via the intradermal (i.d.) route to mice. In the present report, the adjuvant and local skin inflammatory effects of LT-IIa and its B subunit pentamer (LT-IIaB(5)) were determined. When coadministered with ovalbumin (OVA), LT-IIa and, to a lesser extent, LT-IIaB(5) exhibited serum IgG adjuvant effects. In addition, LT-IIa but not LT-IIaB(5) induced T cell-specific anti-OVA responses, particularly in respect to induction of antigen-specific cytotoxic CD8(+) T cell responses. LT-IIa and LT-IIaB(5) induced differential tissue permeability and local inflammatory reactions after i.d. injection. Of particular interest was the reduced or complete lack of local reactions, such as edema and tissue induration, in mice i.d. inoculated with LT-IIa and LT-IIaB(5,) respectively, compared with mice immunized with LT-I. In conclusion, the present results show that LT-IIa and, to a lesser extent, LT-IIaB(5) exert adjuvant effects when they are delivered via the i.d. route. In addition, the low inflammatory effects of LT-IIa and LT-IIaB(5) in comparison to those of LT-I support the usefulness of LT-IIa and LT-IIaB(5) as parenterally delivered vaccine adjuvants.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677110      PMCID: PMC3147343          DOI: 10.1128/CVI.00012-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  40 in total

Review 1.  Efficacy of intradermal vaccination.

Authors:  B D Hunsaker; L J Perino
Journal:  Vet Immunol Immunopathol       Date:  2001-05-10       Impact factor: 2.046

2.  A permeability factor (toxin) found in cholera stools and culture filtrates and its neutralization by convalescent cholera sera.

Authors:  J P Craig
Journal:  Nature       Date:  1965-08-07       Impact factor: 49.962

3.  Microtiter ganglioside enzyme-linked immunosorbent assay for vibrio and Escherichia coli heat-labile enterotoxins and antitoxin.

Authors:  D A Sack; S Huda; P K Neogi; R R Daniel; W M Spira
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

4.  Risk of anaphylaxis after vaccination of children and adolescents.

Authors:  Kari Bohlke; Robert L Davis; S M Marcy; M M Braun; Frank DeStefano; Steven B Black; John P Mullooly; Robert S Thompson
Journal:  Pediatrics       Date:  2003-10       Impact factor: 7.124

5.  Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain.

Authors:  H C Guillobel; J I Carinhanha; L Cárdenas; J D Clements; D F de Almeida; L C Ferreira
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 6.  Immunomodulation using bacterial enterotoxins.

Authors:  C P Simmons; M Ghaem-Magami; L Petrovska; L Lopes; B M Chain; N A Williams; G Dougan
Journal:  Scand J Immunol       Date:  2001-03       Impact factor: 3.487

Review 7.  Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.

Authors:  Jan Holmgren; Cecil Czerkinsky; Kristina Eriksson; Ali Mharandi
Journal:  Vaccine       Date:  2003-06-01       Impact factor: 3.641

8.  Effect of Escherichia coli enterotoxins on macromolecular absorption.

Authors:  M Verma; S Majumdar; N K Ganguly; B N Walia
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

9.  The Type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamers differentially induce and regulate cytokine production in human monocytic cells.

Authors:  George Hajishengallis; Hesham Nawar; Richard I Tapping; Michael W Russell; Terry D Connell
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

10.  Cytotoxic T cell adjuvant effects of three Salmonella enterica flagellins.

Authors:  Catarina J M Braga; Liliana M Massis; Bruna C G Alencar; Maurício M Rodrigues; M E Sbrogio-Almeida; Luís C S Ferreira
Journal:  Braz J Microbiol       Date:  2008-03-01       Impact factor: 2.476

View more
  9 in total

Review 1.  Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.

Authors:  George Hajishengallis; Terry D Connell
Journal:  Vet Immunol Immunopathol       Date:  2012-09-26       Impact factor: 2.046

2.  Enhancement of humoral immunity by the type II heat-labile enterotoxin LT-IIb is dependent upon IL-6 and neutrophils.

Authors:  Christopher J Greene; John C Hu; David J Vance; Yinghui Rong; Lorrie Mandell; Natalie King-Lyons; Patricia Masso-Welch; Nicholas J Mantis; Terry D Connell
Journal:  J Leukoc Biol       Date:  2016-04-08       Impact factor: 4.962

3.  Comparative Adjuvant Effects of Type II Heat-Labile Enterotoxins in Combination with Two Different Candidate Ricin Toxin Vaccine Antigens.

Authors:  David J Vance; Christopher J Greene; Yinghui Rong; Lorrie M Mandell; Terry D Connell; Nicholas J Mantis
Journal:  Clin Vaccine Immunol       Date:  2015-10-21

4.  Cell clustering and delay/arrest in T-cell division implicate a novel mechanism of immune modulation by E. coli heat-labile enterotoxin B-subunits.

Authors:  Seham El-Kassas; Rawah Faraj; Karmarcha Martin; George Hajishengallis; Terry D Connell; Toufic Nashar
Journal:  Cell Immunol       Date:  2015-03-05       Impact factor: 4.868

5.  Intradermal administration of the Type II heat-labile enterotoxins LT-IIb and LT-IIc of enterotoxigenic Escherichia coli enhances humoral and CD8+ T cell immunity to a co-administered antigen.

Authors:  John C Hu; Camila Mathias-Santos; Christopher J Greene; Natalie D King-Lyons; Juliana F Rodrigues; George Hajishengallis; Luís C S Ferreira; Terry D Connell
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

6.  Highly Pathogenic Avian Influenza H5 Hemagglutinin Fused with the A Subunit of Type IIb Escherichia coli Heat Labile Enterotoxin Elicited Protective Immunity and Neutralization by Intranasal Immunization in Mouse and Chicken Models.

Authors:  Neos Tang; Shi-Wei Lin; Ting-Hsuan Chen; Jia-Tsrong Jan; Hung-Yi Wu; Suh-Chin Wu
Journal:  Vaccines (Basel)       Date:  2019-11-22

Review 7.  Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands.

Authors:  Deana N Toussi; Paola Massari
Journal:  Vaccines (Basel)       Date:  2014-04-25

8.  LT-IIb(T13I), a non-toxic type II heat-labile enterotoxin, augments the capacity of a ricin toxin subunit vaccine to evoke neutralizing antibodies and protective immunity.

Authors:  Christopher J Greene; Chrystal M Chadwick; Lorrie M Mandell; John C Hu; Joanne M O'Hara; Robert N Brey; Nicholas J Mantis; Terry D Connell
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

9.  Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein.

Authors:  Denicar Lina Nascimento Fabris Maeda; Milene Tavares Batista; Lennon Ramos Pereira; Mariana de Jesus Cintra; Jaime Henrique Amorim; Camila Mathias-Santos; Sara Araújo Pereira; Silvia Beatriz Boscardin; Sandriana Dos Ramos Silva; Eliana L Faquim-Mauro; Vanessa Barbosa Silveira; Danielle Bruna Leal Oliveira; Stephen Albert Johnston; Luís Carlos de Souza Ferreira; Juliana Falcão Rodrigues
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.